A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.

Competing Interests: Dr Netuka discloses relationships with CARMAT SA (consultant and investigator, advisory board member), Fineheart SA (consultant and investigator, advisory board member), LeviticusCardio (advisory board member, board member, stockholder), and Abbott (consultant, institutional support); Dr Tucanova discloses relationships with Abbott (consultant, institutional support) and Fineheart SA (institutional support); Dr Ivak discloses relationships with CARMAT SA (consultant), Abbott (consultant, institutional support), and Fineheart SA (institutional support); Dr Riha discloses relationships with Abbott (consultant, institutional support), Carmat SA (institutional support), and Fineheart SA (institutional support); Dr Connors reports receiving personal consulting fees from Abbott, Alnylam, Werfen, Bayer, Pfizer, BMS Scientific, Sanofi, Roche, and Anthos for serving as a speaker or advisor outside the submitted work; and Dr Mehra reports consulting fees derived from Abbott (paid to his institution), Natera, Paragonix, Moderna, NupulseCV, Fineheart, Transmedics, Leviticus, Cadrenal, and Second Heart Assist. The remaining authors have no relevant disclosures other than institutional support for the study from Abbott.